𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The tumor-specific de2–7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR

✍ Scribed by Luwor, Rodney B; Zhu, Hong-Jian; Walker, Francesca; Vitali, Angela A; Perera, Rushika M; Burgess, Antony W; Scott, Andrew M; Johns, Terrance G

Book ID
110068937
Publisher
Nature Publishing Group
Year
2004
Tongue
English
Weight
275 KB
Volume
23
Category
Article
ISSN
0950-9232

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Novel monoclonal antibody specific for t
Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene
✍ Terrance G. Johns; Elisabeth Stockert; Gerd Ritter; Achim A. Jungbluth; H-J. Su 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 592 KB

## Abstract In some respects, the EGFR appears to be an attractive target for tumor‐targeted antibody therapy: it is overexpressed in many types of epithelial tumor and inhibition of signaling often induces an anti‐tumor effect. The use of EGFR specific antibodies, however, may be limited by uptake

Response to dual blockade of epidermal g
Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor
✍ Shirish M. Gadgeel; Shadan Ali; Philip A. Philip; Fakhara Ahmed; Antoinette Wozn 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 332 KB 👁 1 views

## Abstract ## BACKGROUND. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have demonstrated clinical benefit in patients with nonsmall cell lung cancer (NSCLC), particularly those with tumors that have EGFR‐TK domain mutations. Moreover, the EGFR and cyclooxygenase (COX)‐2